GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-03-24| Licensing

Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio

by Joy Lin
Share To

Moderna has entered a partnership with Generation Bio to combine their technologies and develop lipid nanoparticles using Generation Bio’s stealth cell-targeted lipid nanoparticle (ctLNP) delivery system. The collaboration is expected to advance the companies’ respective pipelines of non-viral genetic medicines. 

“Through this collaboration, which builds on Generation Bio’s non-viral genetic medicines platform, we have the potential to target immune cells with diverse nucleic acid cargos and the liver for gene replacement. We are excited to have Generation Bio as our partner as we continue to broaden our therapeutic pipeline and extend the potential benefit of nucleic acid therapeutics to more patients,” said Rose Loughlin, Ph.D., Moderna’s Senior Vice President for Research and Early Development.

Phillip Samayoa, Ph.D., Chief Strategy Officer of Generation Bio, added that non-viral DNA therapeutics could offer durable, redosable, and titratable genetic medicines to patients with rare diseases. 

“This collaboration represents a foundational investment in our platform science, both deepening our pipeline of rare and prevalent liver disease programs beyond hemophilia A and accelerating our work to reach outside of the liver with nucleic acid therapies,” he said. 

Related Article: Merck Strikes $50 Million Deal with ModeX For Rights to EBV Vaccine

Moderna Given Option to Advance Immune Cell and Liver Programs

The collaboration gives Moderna an option to license Generation Bio’s ctLNP and close-ended DNA (cdDNA) technology for two immune cell programs and two liver programs. Moderna could also opt into a third immune cell or liver program. 

Moderna will pay Generation Bio $40 million upfront and make a  $36 million equity investment at a premium over recent share prices. The agreement also allows Moderna to participate in a future financing round by Generation Bio.

Furthermore, Moderna will fund all collaboration work, including a pre-payment for research. The collaboration may also bring Generation Bio additional milestone payments and product royalties. 

Finally, the companies will advance in vivo immune cell targeting as a new class of genetic medicines. Any products that Moderna develops using ctLNP technology could generate exclusivity fees, milestone payments, and royalties for Generation Bio.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
2025-01-22
Moderna and Mitsubishi Tanabe Pharma Partner on mRNA Respiratory Vaccines in Japan
2024-07-11
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top